Soligenix, Inc. (SNGX)

US — Healthcare Sector
Peers: ZURA  APGN  PHIO  EFTR  IMMX  ADXN  ACGN  ERYP  ATXI  PALI  CFRX  ALLR  CNSP  WINT  DRMA  ENSC  PBLA  BXRX 

Automate Your Wheel Strategy on SNGX

With Tiblio's Option Bot, you can configure your own wheel strategy including SNGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNGX
  • Rev/Share 0.0008
  • Book/Share 1.1846
  • PB 1.6462
  • Debt/Equity 0.0219
  • CurrentRatio 11.256
  • ROIC -1.4049

 

  • MktCap 6365483.0
  • FreeCF/Share -2.7556
  • PFCF -0.7575
  • PE -0.9363
  • Debt/Assets 0.0102
  • DivYield 0
  • ROE -1.483

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
SNGX
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral

PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.

Read More
image for news Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
SNGX
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral

Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of CiVax™, a thermostabilized subunit vaccine against SARS-CoV-2.

Read More
image for news Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

About Soligenix, Inc. (SNGX)

  • IPO Date 1994-04-04
  • Website https://www.soligenix.com
  • Industry Biotechnology
  • CEO Dr. Christopher J. Schaber Ph.D.
  • Employees 14
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.